B. Mennecier

机构：Centre Hospitalier Régional et Universitaire de Nancy, Délégation Centre-Est, Université de Strasbourg · ORCID：0000-0002-2321-4269

发表论文 161 篇 · 总被引 4151 次 · h-index 21

代表论文

• Lorlatinib for advanced anaplastic lymphoma kinase–positive non–small cell lung cancer: Results of the IFCT-1803 LORLATU cohort (2022 · European Journal of Cancer · 被引 26)
• Patient-reported outcomes in CodeBreaK 200: Sotorasib versus docetaxel for previously treated advanced NSCLC with KRAS G12C mutation (2024 · Lung Cancer · 被引 18)
• Central nervous system complications of immune checkpoint inhibitors: A comprehensive review (2024 · Critical Reviews in Oncology/Hematology · 被引 16)
• Brigatinib for Pretreated, ALK-Positive, Advanced Non-Small-Cell Lung Cancers: Long-Term Follow-Up and Focus on Post-Brigatinib Lorlatinib Efficacy in the Multicenter, Real-World BrigALK2 Study (2022 · Cancers · 被引 9)
• Real-life clinical management patterns in extensive-stage small cell lung cancer across France: a multi-method study (2024 · BMC Cancer · 被引 3)
• 223MO Five-year outcomes of participants with pathological complete response (pCR) enrolled in the KEYNOTE-671 trial of perioperative pembrolizumab (pembro) in early-stage NSCLC (2026 · ESMO Open · 被引 2)